The stock of Entellus Medical Inc (NASDAQ:ENTL) is a huge mover today! The stock decreased 10.23% or $1.92 during the last trading session, hitting $16.85. About 175,238 shares traded hands or 285.99% up from the average. Entellus Medical Inc (NASDAQ:ENTL) has risen 2.62% since April 4, 2016 and is uptrending. It has outperformed by 1.53% the S&P500.
The move comes after 6 months negative chart setup for the $299.60 million company. It was reported on Nov, 4 by Barchart.com. We have $14.66 PT which if reached, will make NASDAQ:ENTL worth $38.95 million less.
Entellus Medical Inc (NASDAQ:ENTL) Ratings Coverage
Out of 2 analysts covering Entellus Medical (NASDAQ:ENTL), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Entellus Medical has been the topic of 4 analyst reports since August 9, 2015 according to StockzIntelligence Inc. As per Thursday, October 6, the company rating was initiated by Deutsche Bank. Canaccord Genuity maintained the shares of ENTL in a report on Sunday, August 9 with “Buy” rating. Piper Jaffray maintained it with “” rating and $27 target price in Tuesday, September 29 report. BTIG Research initiated the shares of ENTL in a report on Tuesday, June 14 with “Buy” rating.
According to Zacks Investment Research, “Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota.”
More notable recent Entellus Medical Inc (NASDAQ:ENTL) news were published by: Marketwatch.com which released: “Entellus Medical started at buy with $26 stock price target at Deutsche Bank” on January 29, 2015, also Globenewswire.com with their article: “Entellus Medical Announces Third Quarter 2016 Financial Results” published on November 03, 2016, Globenewswire.com published: “Entellus Medical Acquires XeroGelâ„¢ from CogENT Therapeutics®, Strengthens …” on June 29, 2016. More interesting news about Entellus Medical Inc (NASDAQ:ENTL) were released by: Seekingalpha.com and their article: “Entellus Medical: This Could Balloon Into Something Big!” published on May 16, 2016 as well as Bizjournals.com‘s news article titled: “Entellus Medical plots growth after successful IPO” with publication date: March 20, 2015.
ENTL Company Profile
Entellus Medical, Inc., incorporated on August 10, 2006, is a medical technology company. The Firm is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation. The Company’s XprESS family of products is used to treat patients with inflammation of the frontal, ethmoid, sphenoid and maxillary sinuses.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.